Trivalent T Cell Receptor Peptide Vaccine for Treatment of Multiple Sclerosis Targets Predominant V Genes Widely Implicated in Autoimmune Diseases and Allergy

2007 ◽  
pp. 369-408 ◽  
Author(s):  
Arthur A. Vandenbark ◽  
Nicole E. Culbertson
Keyword(s):  
Multiple Sclerosis ◽  
T Cell ◽  
Autoimmune Diseases ◽  
T Cell Receptor ◽  
Peptide Vaccine ◽  
Cell Receptor ◽  
V Genes

scholarly journals Therapeutic vaccination with a trivalent T-cell receptor (TCR) peptide vaccine restores deficient FoxP3 expression and TCR recognition in subjects with multiple sclerosis

Immunology ◽  
2008 ◽  
Vol 123 (1) ◽  
pp. 66-78 ◽  
Author(s):  
Arthur A. Vandenbark ◽  
Nicole E. Culbertson ◽  
Richard M. Bartholomew ◽  
Jianya Huan ◽  
Marci Agotsch ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
T Cell ◽  
T Cell Receptor ◽  
Peptide Vaccine ◽  
Foxp3 Expression ◽  
Cell Receptor ◽  
Therapeutic Vaccination

A highly immunogenic trivalent T cell receptor peptide vaccine for multiple sclerosis

2005 ◽  
Vol 11 (5) ◽  
pp. 552-561 ◽  
Author(s):  
D N Bourdette ◽  
E Edmonds ◽  
C Smith ◽  
J D Bowen ◽  
C RG Guttmann ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
T Cell ◽  
T Cell Receptor ◽  
Peptide Vaccine ◽  
Cell Receptor ◽  
Peptide Vaccination ◽  
Injection Site Reactions ◽  
Novel Approach ◽  
Incomplete Freund’S Adjuvant ◽  
To Receive

Background: T cell receptor (TCR) peptide vaccination is a novel approach to treating multiple sclerosis (MS). The low immunogenicity of previous vaccines has hindered the development of TCR peptide vaccination for MS. Objective: To compare the immunogenicity of intramuscular injections of TCR BV5S2, BV6S5 and BV13S1 CDR2 peptides in incomplete Freund’s adjuvant (IFA) with intradermal injections of the same peptides without IFA. Methods: MS subjects were randomized to receive TCR peptides/IFA, TCR peptides/saline or IFA alone. Subjects were on study for 24 weeks. Results: The TCR peptides/IFA vaccine induced vigorous T cell responses in 100% of subjects completing the 24-week study (9/9) compared with only 20% (2/10) of those receiving the TCR peptides/saline vaccine (P =0.001). IFA alone induced a weak response in only one of five subjects. Aside from injection site reactions, there were no significant adverse events attributable to the treatment. Conclusions: The trivalent TCR peptide in IFA vaccine represents a significant improvement in immunogenicity over previous TCR peptide vaccines and warrants investigation of its ability to treat MS.

Immunity to T cell receptor peptides in multiple sclerosis. III. Preferential immunogenicity of complementarity determi4ning region 2 peptides from disease-associated TCR BV

1998 ◽  
Vol 90 (1) ◽  
pp. 78 ◽  
Author(s):  
D.N. Bourdette ◽  
Y.K. Chou ◽  
R.H. Whitman ◽  
J. Buckner ◽  
G.T. Nepom ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
T Cell ◽  
T Cell Receptor ◽  
Cell Receptor

scholarly journals Erratum: Limited heterogeneity of rearranged T-cell receptor V α transcripts in brains of multiple sclerosis patients

Nature ◽  
1991 ◽  
Vol 353 (6339) ◽  
pp. 94-94 ◽  
Author(s):  
Jorge R. Oksenberg ◽  
Simon Stuart ◽  
Ann B. Begovich ◽  
Robert B. Bell ◽  
Henry A. Erlich ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
T Cell ◽  
T Cell Receptor ◽  
Cell Receptor ◽  
Multiple Sclerosis Patients
Sign in / Sign up

Export Citation Format

Share Document